You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Annualized relapse rate

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing Remitting Multiple Sclerosis (RRMS) Trial in Tehran (Pegylated interferon beta-1a, Interferon Beta-1A Prefilled

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis (RRMS)
  • Pegylated interferon beta-1a
  • Interferon Beta-1A Prefilled Syringe
  • Tehran, Iran, Islamic Republic of
    Sina Hospital
Feb 5, 2022

Patients With Schizophrenia Trial (Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG))

Not yet recruiting
  • Patients With Schizophrenia
  • Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)
  • (no location specified)
May 1, 2023

First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

Active, not recruiting
  • Multiple Sclerosis
  • Alexandroupolis, Greece
  • +52 more
Sep 28, 2022

Asthma Trial in Paris (2: Intervention, 1: Control)

Completed
  • Asthma
  • 2: Intervention
  • 1: Control
  • Paris, France
    Service des Urgences, Hôpital Lariboisière
Mar 9, 2022

Multiple Sclerosis Trial (Frexalimab, Teriflunomide, Placebo infusion)

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Nov 15, 2023

Secondary Progressive Multiple Sclerosis Trial in Isfahan (Rituximab, Glatiramer Acetate)

Completed
  • Secondary Progressive Multiple Sclerosis
  • Isfahan, Iran, Islamic Republic of
    Kashani Hospital
May 22, 2019

Multiple Sclerosis (MS) Trial in Dallas (Alemtuzumab)

Completed
Has Results
  • Multiple Sclerosis (MS)
  • Dallas, Texas
  • +1 more
Jan 24, 2022

Children With Multiple Sclerosis Trial (MRI without injection of contrast product)

Not yet recruiting
  • Children With Multiple Sclerosis
  • MRI without injection of contrast product
  • (no location specified)
Feb 17, 2022

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
Has Results
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Phoenix, Arizona
  • +12 more
Nov 11, 2021

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
Has Results
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Carlsbad, California
  • +13 more
Nov 5, 2021

Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis

Recruiting
  • Relapsing-Remitting Multiple Sclerosis
    • Coventry, United Kingdom
    • +7 more
    May 20, 2022

    Mass Accumulation Rate asPredictive Biomarker in Multiple

    Recruiting
    • Multiple Myeloma in Relapse
      • Duarte, California
      • +5 more
      Jul 13, 2022

      Multiple Sclerosis (MS) Trial in Worldwide (Fingolimod, Ofatumumab, Siponimod)

      Recruiting
      • Multiple Sclerosis (MS)
      • Little Rock, Arkansas
      • +55 more
      Jan 13, 2023

      Multiple Sclerosis, Relapsing-Remitting Trial in Iran, Islamic Republic of (Ocrelizumab (CinnaGen, Iran), Ocrelizumab (Roche,

      Active, not recruiting
      • Multiple Sclerosis
      • Relapsing-Remitting
      • Ocrelizumab (CinnaGen, Iran)
      • Ocrelizumab (Roche, Switzerland)
      • Rasht, Guilan, Iran, Islamic Republic of
      • +14 more
      Aug 31, 2021

      Biochemical Relapse Free Survival, Complications Rates (Erectile Dysfunction, GI, GU Complications) Trial in St Petersburg

      Recruiting
      • Biochemical Relapse Free Survival
      • Complications Rates (Erectile Dysfunction, GI, GU Complications)
      • Stereotactic ablative radiotherapy
      • High dose rate brachytherapy
      • St Petersburg, Russian Federation
        Sergey Novikov
      Apr 28, 2021

      Steroid-Sensitive Nephrotic Syndrome Trial in Islamabad (Prednisolone)

      Recruiting
      • Steroid-Sensitive Nephrotic Syndrome
      • Islamabad, Capital, Pakistan
        Pakistan Institute of Medical Sciences
      May 9, 2021

      Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD Trial

      Not yet recruiting
      • Neuromyelitis Optica Spectrum Disorder
      • +2 more
        • (no location specified)
        Jul 21, 2023

        Multiple Sclerosis Trial in Moscow (BCD-132, Teriflunomide)

        Recruiting
        • Multiple Sclerosis
        • Moscow, Russian Federation
          State Budgetary Healthcare Institution of the Moscow Region M.F.
        May 18, 2022

        Multiple Sclerosis, Relapsing-Remitting Trial in Worldwide (Dimethyl Fumarate, Peginterferon Beta-1a, Placebo)

        Terminated
        • Multiple Sclerosis, Relapsing-Remitting
        • Dimethyl Fumarate
        • +2 more
        • Raleigh, North Carolina
        • +22 more
        Nov 30, 2022

        Insulin Resistance in Egyptian Patients With Multiple Sclerosis

        Not yet recruiting
        • Multiple Sclerosis
        • Insulin Resistance
        • treatment of insulin resistance with appropriate modality according to each patient
        • (no location specified)
        Aug 28, 2023

        Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis Trial in France (Perfusion of treatment Rituximab, Perfusion of

        Not yet recruiting
        • Multiple Sclerosis
        • Relapsing-remitting Multiple Sclerosis
        • Perfusion of treatment Rituximab
        • Perfusion of treatment Ocrelizumab
        • Lyon, Bron, France
        • +22 more
        Mar 6, 2023

        Multiple Sclerosis, Relapsing-Remitting Trial in Amsterdam (Ocrelizumab)

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Amsterdam, Noord-Holland, Netherlands
          Amsterdam UMC, location VU
        Apr 21, 2022

        Relapsing-remitting Multiple Sclerosis Trial (CT-P53, US-Ocrevus, EU-Ocrevus)

        Not yet recruiting
        • Relapsing-remitting Multiple Sclerosis
        • CT-P53
        • +2 more
        • (no location specified)
        Jun 7, 2023

        Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

        Completed
        • Multiple Sclerosis
        • interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
        • Prague, Czechia
          IMPULS Endowment Fund
        Mar 7, 2023

        Multiple Myeloma in Relapse Trial in Canada (Daratumumab)

        Completed
        • Multiple Myeloma in Relapse
        • Kingston, Ontario, Canada
        • +5 more
        Feb 14, 2022